Gray, John - University of California, Davis - College of Biological Sciences

研究领域

Research in Dr. Gray’s laboratory focuses on understanding the molecular and cellular mechanisms involved in synapse development and plasticity throughout the brain. In particular, Dr. Gray’s laboratory studies the regulation of the NMDA-type glutamate receptors that play crucial roles in synapse development and synaptic plasticity. In addition, NMDA receptors have been implicated in a broad range of neuropsychiatric disorders, including schizophrenia, autism, addiction, Alzheimer’s disease, Huntington’s disease and ischemia. By combining innovative genetic approaches with electrophysiology and imaging to gain a detailed understanding of the molecular mechanisms involved in the regulation of NMDA receptors and synapses, Dr. Gray’s laboratory is striving to open new frontiers for the development of disease-modifying therapeutic approaches for complex neuropsychiatric disorders.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Gray JA, Zito K, and Hell JW (2016). Non-ionotropic signaling by the NMDA receptor: controversy and opportunity. F1000Research, 5(F1000 Faculty Rev): 1010. Stein IS, Gray JA, and Zito K (2015). Non-ionotropic NMDA receptor signaling drives activity-induced dendritic spine shrinkage. Journal of Neuroscience, 35(35): 12303-12308. Gray JA (2015). Tardive Dyskinesia, in Ferri’s Clinical Advisor 2016. Ferri FF (Ed.), Mosbi, Philadelphia, PA, p 1198. Gray JA and Nicoll RA (2014). Introduction to the Pharmacology of CNS Drugs, in Basic and Clinical Pharmacology. Katzung BG (Ed.), McGraw-Hill, New York, NY, pp 355-368. Sanz-Clemente A, Gray JA, Nicoll RA, and Roche KW (2013). Activated CaMKII couples GluN2B and Casein Kinase 2 to control synaptic NMDA receptors. Cell Reports, 3(3): 607-614. Gray JA and Nicoll RA (2012). Thinking outside the synapse: glycine at extrasynaptic NMDA receptors. Cell, 150(3): 455-456. Chen BS*, Gray JA*, Sanz-Clemente A, Wei Z, Thomas EV, Nicoll RA, and Roche KW (2012). SAP102 mediates synaptic clearance of NMDA receptors. Cell Reports, 2(5): 1120-1128. (*co-first authors) Gray JA (2012). Parkinsonism and rabbit syndrome following discontinuation of low-dose ziprasidone and concomitant initiation of sertraline. Journal of Clinical Psychopharmacology, 32(1): 142-143. Gray JA, Shi Y, Usui H, During MJ, Sakimura K, Nicoll RA (2011). Distinct modes of AMPA receptor suppression at developing synapses by GluN2A and GluN2B: single-cell NMDA receptor subunit deletion in vivo. Neuron, 71(6): 1085-1101. Lu W*, Gray JA*, Granger AJ, During MJ, Nicoll RA (2011). The potentiation of synaptic AMPA receptors induced by the deletion of NMDA receptors requires the GluA2 subunit. Journal of Neurophysiology, 105(2): 923-928. (*co-first authors) Granger AJ, Gray JA, Lu W, and Nicoll RA (2011). Genetic analysis of neuronal ionotropic glutamate receptor subunits. Journal of Physiology, 589(17): 4095-4101. Juge N, Gray JA, Omote H, Miyaji T, Inoue T, Hara C, Uneyama H, Edwards RH, Nicoll RA, Moriyama Y (2010). Metabolic control of vesicular glutamate transport and release. Neuron, 68(1): 99-112. Gray JA and Risch SC (2009). When clozapine is not enough. Augment with lamotrigine? Current Psychiatry, 8(1): 41-46. Berger M, Gray JA, and Roth BL (2009). The expanded biology of serotonin. Annual Review of Medicine, 60: 355-366. Gray JA and Roth BL (2009). Intraneuronal Signaling, in Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Sadock BJ, Sadock VA and Ruiz P (Eds.) Lippincott Williams & Wilkins, Philadelphia, PA, pp 118-129. Gray JA and Roth BL (2007). The pipeline and future of drug development in schizophrenia. Molecular Psychiatry, 12(10): 904-922. Gray JA and Roth BL (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophrenia Bulletin, 33(5): 1100-1119. Gray JA and Roth BL (2007). Serotonin Systems, in Handbook of Contemporary Neuropharmacology. Sibley DR, Hanin I, Kuhar M and Skolnick P (Eds.), John Wiley & Sons, New York, NY, pp 257-298. Gray JA and Roth BL (2006). Developing selectively non-selective drugs for treating CNS disorders. Drug Discovery Today: Therapeutic Strategies, 3(4): 413-419. Xia Z, Hufeisen SJ, Gray JA, and Roth BL (2003). The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience, 122(4): 907-920. Gray JA, Compton-Toth BA, and Roth BL (2003). Identification of two serine residues essential for agonist-induced 5-HT2A receptor desensitization. Biochemistry, 42(36): 10853-10862. Xia Z, Gray JA, Compton-Toth BA, and Roth BL (2003). A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. Journal of Biological Chemistry 278(24): 21901-21908. Gray JA, Bhatnagar A, Gurevich VV, and Roth BL (2003). The interaction of a constitutively active arrestin with the arrestin-insensitive 5-HT2A receptor induces agonist-independent internalization. Molecular Pharmacology 63(5): 961-972. Gray JA and Roth BL (2002). A Last GASP for GPCRs? Science 297: 529-531. Gray JA, Sheffler DJ, Bhatnagar A, Woods JA, Hufeisen SJ, Benovic JL, and Roth BL (2001). Cell-type specific effects of endocytosis inhibitors on 5-HT2A receptor desensitization and resensitization reveal an arrestin-, GRK2- and GRK5-independent mode of regulation in HEK-293 cells. Molecular Pharmacology 60(5): 1020-1030.